SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is gaining attention as discussions emerge around decentralized data storage solutions and its potential to disrupt the cloud storage market, particularly Amazon's AWS. Community members are pointing to Filecoin's real-world applications and partnerships, sparking speculation about a significant price surge. Some traders believe Filecoin is undervalued and exhibits signs of a breakout, while others reference its previous cycles.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential to disrupt the cloud computing industry and integrate AI, with some drawing comparisons to ZCash's previous run. Bullish sentiment is fueled by recent news around the Caffeine AI platform and increased developer activity, as well as speculation about potential partnerships and exchange listings. Community members highlight ICP's unique technology and its potential to offer a decentralized alternative to traditional cloud providers like AWS and Azure.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending as community members discuss its potential within the expanding Jasmy ecosystem, particularly around the JANCTION project and its JCT token, while also debating price action and future prospects. The discussions include speculation on potential partnerships and the impact of broader market trends. Some community members are highlighting the coin's fundamentals, while others express frustration with price movement.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to ongoing speculation around a potential buyout offer from pharmaceutical giants like $PFE and $NVO, driving community discussion about competing bids and the future of its obesity drug pipeline. The community is actively debating the potential value of MTSR's assets, with some believing the bidding war is far from over, while others suggest that potential regulatory hurdles or superior alternatives may shift focus elsewhere. Broader sector trends in weight-loss and metabolic disease treatments add further context.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings ($ONDS) is trending due to its acquisition of Sentrycs, a counter-drone technology firm, sparking discussions about its potential in the defense sector. The community is focused on how this acquisition will impact Ondas' future contracts and revenue, especially given the increasing need for counter-UAS solutions globally. Bullish sentiment is fueled by the anticipation of strong earnings and the company's strategic positioning in the growing drone and counter-drone market.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is trending as traders discuss its potential following the Rezolve AI acquisition, with many focusing on its recent price volatility and speculating about future pumps. Community members are actively debating entry points and potential targets, while also considering the impact of $RZLV's involvement and revenue allocation. Some traders express bullish sentiment, citing strong buying pressure and potential for a breakout, while others remain cautious due to past performance.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to an ongoing bidding war with Novo Nordisk ($NVO) to acquire Metsera ($MTSR), an obesity drug developer. The community is discussing the implications of Pfizer potentially overpaying for Metsera and whether antitrust concerns will play a role, as well as potential alternative acquisitions like Viking Therapeutics ($VKTX). Some investors are also expressing concerns about Pfizer's overall acquisition strategy and its impact on shareholder value.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to its active and growing community rallying around various initiatives, including Kendu Games and Kendu Spice, with holders emphasizing the project's real-world applications. The community highlights its strong conviction, consistent building, and expanding IRL presence as key reasons for its bullish sentiment. Discussions also revolve around strategic accumulation during market dips and Certik ratings.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors discuss its potential as a meme stock with a possible short squeeze, highlighting its low float and upcoming pension transfer. The community is also focused on Kodak's diversification into batteries and pharmaceuticals, and some are anticipating news or partnerships that could drive the stock higher. Despite mixed sentiment, many are optimistic about the company's long-term growth potential.

Toyota Motor Corp. engages in the manufacture and sale of motor vehicles and parts. It operates through the following segments: Automotive, Financial Services, and All Other. The Automotive segment designs, manufactures, assembles and sells passenger cars, minivans, trucks, and related vehicle parts and accessories. It is also involved in the development of intelligent transport systems. The Financial Services segment offers purchase or lease financing to Toyota vehicle dealers and customers. It also provides retail leasing through lease contracts purchased by dealers. The All Others segment deals with the design, manufacture, and sale of housing, telecommunications and other businesses. The company was founded by Kiichiro Toyoda on August 28, 1937 and is headquartered in Toyota, Japan.

Toyota Motor Corporation - ADR

Toyota Motor Corp.

Toyota is trending as community members discuss the company's advancements in solid-state battery technology and its potential impact on the EV sector, in addition to a potential buy-out of Toyota Industries. Some are analyzing recent earnings and the company's strategic direction, with discussion about tariffs and sales growth, along with Toyota's collaboration with Waymo, as factors influencing the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.In after-hours trading on Wednesday, Mereo BioPharma dropped 38.8% to $1.80, while Ultragenyx fell 25.8% to $30.76.UX143 is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. It is being jointly developed by Ultragenyx and Mereo BioPharma.The Data Monitoring Committee (DMC) reviewed the Orbit study and found that the treatment’s safety profile appeared acceptable, recommending continuation to&nbsp;the final analysis.Final results from both the Orbit and Cosmic studies are expected to be released around the end of the year.The Orbit trial is testing UX143 in patients aged 5 to 25 with osteogenesis imperfecta, a condition characterized by brittle bones.&nbsp;Participants are receiving either the experimental treatment or a placebo, with the&nbsp;primary focus on&nbsp;the frequency of&nbsp;fractures.&nbsp;After the&nbsp;primary data is collected, all patients will move to open-label treatment.The Cosmic trial is running in parallel for children aged 2 to 7, comparing UX143 to standard bisphosphonate therapy.&nbsp;The study is also ongoing, with final results expected after patients&nbsp;have completed at least 18 months of treatment.On Stocktwits, retail sentiment for both&nbsp;<a href="https://stocktwits.com/symbol/MREO">Mereo BioPharma</a> and&nbsp;<a href="https://stocktwits.com/symbol/RARE">Ultragenyx</a> was tagged as ‘extremely bullish’ with ‘extremely high’ message volume.Some users&nbsp;suggested that the market was overreacting to the update from Mereo BioPharma and Ultragenyx, with one describing Mereo as a “good medium to long-term candidate” and another&nbsp;attributing the drop to a retail misunderstanding of standard clinical trial practices.<stembedurl>https://stocktwits.com/LogicalTrading/message/620417028</stembedurl><stembedurl>https://stocktwits.com/JCobb1/message/620403932</stembedurl>One comment noted that the final analysis will use a conventional 0.05 p-value threshold and expressed optimism about the chances of success, while an Ultragenyx watcher speculated the market was prematurely pricing in study failure.<stembedurl>https://stocktwits.com/RenHenInvestments/message/620415451</stembedurl><stembedurl>https://stocktwits.com/bhavn008/message/620395599</stembedurl>While Ultragenyx’s stock has risen 0.7% so far in 2025, Mereo’s stock&nbsp;has declined 14% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ultragenyx (RARE) and Mereo BioPharma (MREO) slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 as initially planned/ Photo credit: Getty Images

Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.

Equity

The companies now expect final data from the Orbit and Cosmic studies by the end of the year.

Ultragenyx Posts New Data From Bone Disease Study

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating...

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

Mereo BioPharma Group (MREO, $3.41) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that MREO's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Needham & Company LLC Boosts Mereo BioPharma Group (NASDAQ:MREO) Price Target to $6.00

Mereo BioPharma Group (NASDAQ:MREO - Free Report) had its price target lifted by Needham & Company LLC from $5.00 to $6.00 in a report published on Thursday, Benzinga reports. Needham & Company LLC...

Mereo BioPharma Group plc (MREO, $3.3) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling MREO's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Mereo BioPharma Group (NASDAQ:MREO) Price Target Raised to $6.00

Mereo BioPharma Group (NASDAQ:MREO  Get Free Report) had its target price hoisted by equities research analysts at Needham  Company LLC from $5.00 to $6.00 in a research report issued on...

Mereo BioPharma Group (MREO, $3.02) RSI Indicator left the oversold zone on March 27, 2024

This is a signal that MREO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results

Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024Related Stocks: MREO...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$1.80
Prev Close	$1.76
Open	$1.74
Dividend Yield	0.00%
50-Day Moving Average	$1.90
Beta	1.21
Avg. Volume	1.58M
PE Ratio	-5.66

52-Week High	$4.40
52-Week Low	$1.47
Market Capitalization	$279.84M
EPS (Annual)	-$0.2925
Price to Book	5.28
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MREO
Mereo Biopharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MREO News

MREOMereo Biopharma